SVB starts Trevi at 'outperform' on cough, itch treatment potential

Trevi Therapeutics

22/11/2022 19:35

** SVB Securities initiates coverage of drug developer Trevi
Therapeutics Inc  TRVI.O  with "outperform" rating 
    ** Brokerage assigns $6 PT on prospects of oral candidate
Haduvio to address chronic cough and itch in idiopathic
pulmonary fibrosis (IPF) and prurigo nodularis (PN) patients
    ** IPF is a condition in which the lungs become scarred and
breathing becomes increasingly difficult, while PN is a skin
disease characterized by itchy nodules usually on arms or legs
    ** SVB sees revenue of ~$875 mln for Haduvio in IPF
treatment market on strength of positive mid-stage data reported
in September 
    ** Brokerage also models the oral candidate to generate
~$490 mln in PN targeted market based on its mid-to-late-stage
study meeting main goal in June
    ** TRVI is expected to begin second phase dose-ranging
mid-stage trial of Haduvio in PN by first-half of 2023
    ** Haduvio's further development in PN pivotal study is
pending partnership as TRVI focuses its current resources on the
chronic cough franchise - SVB
    ** Including session moves, TRVI up 142.9% YTD
 (Reporting by Pratik Jain)
 ((Pratik.Jain@thomsonreuters.com;))